Trial · NCT01587339
Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy
NCT01587339, Completed, GlaxoSmithKline
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy. Trials, record NCT01587339. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01587339
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy
- NCT number
- NCT01587339
- Status
- Completed
- Enrollment
- 6,498 participants, actual
- Lead sponsor
- GlaxoSmithKline
- Conditions
- Epilepsy
- Interventions
- retigabine/ezogabine, lacosamide, zonisamide, pregabalin, eslicarbazepine
- First posted
- 2012-04-30
- Last updated
- 2013-09-16
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Responder Rate | Duration of studies included in the systematic review up to 28 weeks of double blind period | Proportion of patients who respond to treatment (50% reduction in seizure frequency from baseline) |
| Primary | Median Seizure reduction | Duration of studies included in the systematic review up to 28 weeks of double blind period | Median percent reduction in seizure frequency from baseline |
| Primary | Seizure severity | Duration of studies included in the systematic review up to 28 weeks of double blind period | Seizure severity (any definitions acceptable) |
| Primary | Time to onset of treatment effect | Duration of studies included in the systematic review up to 28 weeks of double blind period | Time to onset of treatment effect |
| Primary | Seizure free patients | Duration of studies included in the systematic review up to 28 weeks of double blind period | Proportion of patients who are seizure free (and time period over which this was measured) |
| Primary | Changes in HRQoL | Duration of studies included in the systematic review up to 28 weeks of double blind period | Changes in HRQoL |
| Primary | All drop outs | Duration of studies included in the systematic review up to 28 weeks of double blind period | Proportion of patients who drop out of the studies for any reason |
| Primary | Drop outs due to AE | Duration of studies included in the systematic review up to 28 weeks of double blind period | Proportion of patients who drop out of the studies (as a result of adverse events i.e. tolerability) |
| Primary | Adverse events | Duration of studies included in the systematic review up to 28 weeks of double blind period | Percentage of patients reporting 5 key adverse events identified by the Cochrane Epilepsy Group as common and important adverse effects of antiepileptic drugs: ataxia, dizziness, fatigue, nausea or somnolence |
| Primary | Mortality | Duration of studies included in the systematic review up to 28 weeks of double blind period | Mortality |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 22902288 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01587339
GET https://conductscience.org/api/trials/v1/NCT01587339/registered